Final program*
- 06:00 - 10:00 pm, CET
Get Together at the Mercure MOA Berlin
Conference Day 1: Tuesday, November 9th, 2021 8:00 am - 4:45 pm, CET
For onsite participants:
- 04:45 - 06:30 / 07:00 pm, CET
Poster Session & Exhibition
- 06:30 / 07:00 - 10:00 pm, CET
Evening Event at Mercure MOA Hotel Berlin
Opening:
Welcome & Logistics
- 08:00 - 08:15 am, CET
- 08:00 - 08:15 am, CET
- Opening: Welcome & Logistics
- Franz-Werner Haas
- Chief Executive Officer, CureVac
- 08:15 - 08:20 am, CET
- Introduction of Session I
- Norbert Pardi
- Assistant Professor of Microbiology, University of Pennsylvania
- 08:20 - 08:40 am, CET
- Next generation mRNA vaccine provides robust protection against SARS-CoV-2 challenge in preclinical models
- Susanne Rauch
- Associate Director Infectious Diseases Research, CureVac
- 08:40 - 09:00 am, CET
- mRNA-1273 and the next generation of Moderna vaccines
- Cesar Sanz Rodriguez
- Vice President, Medical Affairs - Europe, Middle East & Africa, Moderna
- 09:00 - 09:20 am, CET (no live Q&A)
- Liposomally formulated mRNA for cancer immune therapy
- Özlem Türeci
- Chief Medical Officer, BioNTech
- 09:20 - 09:25 am, CET
- Introduction of Session II
- Patrick Baumhof
- Senior Vice President Formulation & Delivery, CureVac
- Mustafa Diken
- Vice President of Vaccines & Immunology, BioNTech
- 09:25- 09:45 am, CET
- mRNA-LNP applications for acute and chronic liver diseases
- Valerie Gouon-Evans
- Associate Professor, Boston University School of Medicine and Boston Medical Center
- 09:45 - 10:05 am, CET
- RNA Delivery Beyond the Liver: from Gene Silencing to Gene Editing
- Dan Peer
- Professor & Director of the Laboratory of Precision NanoMedicine, Tel Aviv University
- 10:05 - 10:25 am, CET
- Lipid Nanoparticles for In Utero mRNA Delivery
- Michael J. Mitchell
- Skirkanich Assistant Professor of Innovation, University of Pennsylvania
Coffee Break
- 10:25 - 10:40 am, CET
- 10:40 – 10:55 am, CET
- Oral abstract presentation - Peptide Based Nanoparticle-platform for targeted delivery of functional mRNAs
- Gilles Divita
- Chief Executive Officer, DIVINCELL
- 10:55 - 11:15 am, CET
- Exosome therapeutics – engineering nature’s nanoparticle system to deliver mRNA and other drugs
- Antonin (Tony) de Fougerolles
- Chief Executive Officer, Evox Therapeutics
- 11:15 – 11:35 am, CET
- Developing mRNA-Based Vaccines and Therapeutics
- Padmanabh (Pad) Chivukula
- Chief Scientific Officer, Arcturus Therapeutics
- 11:35 - 11:50 am, CET
- A versatile toolbox for development of RNA LNP-based vaccines, gene therapies and cell therapies
- Martin Rabel
- Field Application Scientist at Precision NanoSystems Inc.
- 11:50 am – 12:10 pm, CET
- Influence of lipid nanoparticle delivery chemistry and mRNA modifications on functional protein distribution in mice
- Kathryn A. Whitehead
- Associate Professor and Dean’s Career Fellow in the Departments of Chemical Engineering and Biomedical Engineering, Carnegie Mellon University
Lunch Break
- 12:10 – 12:50 pm, CET
- 12:50 - 12:55 pm, CET
- Introduction of Session III
- Katalin Karikó
- Senior Vice President RNA Protein Replacement Therapies, BioNTech
- 12:55 – 01:15 pm, CET
- Nucleoside-modified mRNA mediated modulation of organ-specific lymphatic growth and function
- Zoltán Jakus
- Associate Professor, Semmelweis University
CEO Roundtable
- 01:15 - 02:00 pm, CET
-
Host: Naomi Kresge,
Journalist Bloomberg
- 01:15 - 02:00 pm, CET (no live Q&A)
- CEO Roundtable
- mRNA Technology – A game changer for the future of global health
- Stéphane Bancel
- Chief Executive Officer, Moderna
- Ugur Sahin
- Chief Executive Officer, BioNTech
- Franz-Werner Haas
- Chief Executive Officer, CureVac
- 02:00 – 02:20 pm, CET
- The influence of codon optimality on gene expression
- Jeff Coller
- Professor of RNA Biology and Therapeutics, Johns Hopkins University
- 02:20 - 02:40 pm, CET
- Regulation of mRNA translation and decay
- David Bartel
- Professor of Biology, Whitehead Institute for Biomedical Research
Coffee Break
- 02:40 - 03:00 pm, CET
- 03:00 - 03:05 pm, CET
- Introduction of Session IV
- Melissa J. Moore
- Chief Scientific Officer Research Platform, Moderna
- 03:25 - 03:45 pm, CET (no live Q&A)
- Advances in CRISPR/Cas9 Therapeutic Genome Editing for In Vivo and Ex Vivo Applications
- Laura Sepp-Lorenzino
- Chief Scientific Officer, Intellia Therapeutics
- 03:45 - 04:05 pm, CET
- Chemo-enzymatic modifications for altering translational and immunogenic properties of mRNA
- Andrea Rentmeister
- Professor at the Department of Chemistry, Westfälische Wilhelms-Universität Münster
- 04:05 - 04:25 pm, CET
- Harnessing RNA endonucleases to control gene outputs
- Jeremy E. Wilusz
- Associate Professor of Biochemistry & Biophysics, University of Pennsylvania Perelman School of Medicine
- 04:25 - 04:40 pm, CET
- Oral abstract presentation - Correcting metabolic liver diseases by in vivo base editing
- Gerald Schwank
- Professor, University of Zurich
- 04:40 - 04:45 pm, CET
- Concluding Remarks Conference Day 1
- Igor Splawski
- Chief Scientific Officer, CureVac
For onsite participants: Poster Session & Exhibition
- 04:45 - 06:30 / 07:00 pm, CET
Evening Event at Mercure MOA Hotel Berlin
- 06:30 / 07:00 - 10:00 pm, CET
Conference Day 2: Wednesday, November 10th, 2021 8:00 am - 04:30 pm, CET
History of mRNA
- 08:00 - 09:00 am, CET
- 09:00 - 09:05 am, CET
- Introduction of Session V
- Patrick Baumhof
- Senior Vice President Formulation & Delivery, CureVac
- Mathias Vormehr
- Director Cancer Vaccines, BioNTech
- 09:05 - 09:25 am, CET
- Nucleoside-Modified Autoantigen-Encoding mRNA-Vaccine as a Novel Approach for Antigen-Specific Tolerance Induction in Autoimmunity
- Christina Krienke
- Head of the Team Autoimmunity, BioNTech
- 09:25 - 09:45 am, CET
- Treatment of influenza and SARS-CoV-2 infections via mRNA-encoded Cas13a in rodents
- Philip J. Santangelo
- Professor in the Wallace H. Coulter Department of Biomedical Engineering, Emory University
- 09:45 - 10:05 am, CET
- Tumor specific enzyme assited chemotherapy - a novel approach to specifically eradicate malignant resistant cells
- Mikael Björnstedt
- Professor in Pathology, Karolinska Institutet
Coffee Break
- 10:05 - 10:20 am, CET
- 10:20 - 10:40 am, CET
- Combining antibody and RNA-encoded Interleukin-2 overcomes resistance in MHC class I-deficient cancer
- Jan D. Beck
- Scientist Cancer Vaccines, BioNTech
- 10:40 – 10:55 am, CET
- Oral abstract presentation - Regeneration of muscle tissue and function in Stress Urinary Incontinence using engineered RNA
- Friedrich Metzger
- Chief Scientific Officer & Co-Founder, Versameb AG
- 10:55 - 11:10 am, CET
- Oral abstract presentation - Transient VEGFA expression using VEGFA mRNA-LNPs induces Biliary epithelial cell-driven liver regeneration in mouse models of liver injury
- Fatima Rizvi
- Postdoctoral Fellow Center for Regenerative Medicine (CReM), Boston University
- 11:10 - 11:15 am, CET
- Introduction of Session VI
- Norbert Pardi
- Assistant Professor of Microbiology, University of Pennsylvania
- 11:15 - 11:35 am, CET
- Cancer vaccines candidates based on optimised mRNA-LNP formulations tuned for systemic immunization induce strong antitumor immunity by engaging splenic immune cells
- Stefaan De Koker
- Vice President Discovery, eTheRNA immunotherapies
- 11:35 - 11:55 am, CET (no live Q&A)
- IL-1 family members as key regulators of the inflammatory response to RNA vaccines
- Siri Tahtinen
- Postdoctoral Research Fellow at the Department of Cancer Immunology, Genentech Inc.
- 11:55 am - 12:15 pm, CET
- Immune responses to SARS-CoV-2 mRNA vaccines in human lymph nodes
- Michela Locci
- Assistant Professor of Microbiology, Perelman School of Medicine, University of Pennsylvania
- 12:15 - 12:35 pm, CET
- A VLP-mRNA platform for HIV-1 vaccine development
- Paolo Lusso
- Chief Viral Pathogenesis Section, National Institute of Allergy and Infectious Diseases
Lunch Break
- 12:35 - 01:25 pm, CET
- 01:25 - 01:30 pm, CET
- Introduction of Session VII
- Igor Splawski
- Chief Scientific Officer, CureVac
- 01:50 - 02:10 pm, CET
- Engineering Circular RNA Therapeutics
- Aravind Asokan
- Professor & Director of Gene Therapy, Duke University
- 02:10 - 02:30 pm, CET
- The therapeutic potential of oRNA
- Thomas M. Barnes
- Chief Executive Officer, Orna Therapeutics
- 02:30 - 02:45 pm, CET
- Oral abstract presentation - Small circular RNA vaccine
- Guizhi Zhu
- Assistant Professor of the Department of Pharmaceutics, Virginia Commonwealth University
Coffee Break
- 02:45 - 03:05 pm, CET
- 03:05 - 03:10 pm, CET
- Introduction of Session VIII
- Patrick Baumhof
- Senior Vice President Formulation & Delivery, CureVac
- 03:10 - 03:25 pm, CET
- Room to grow - strategies to scale up mRNA manufacturing
- Katarina Stenklo
- Enterprise Solutions Commercial Activation Leader, Cytiva
- 03:25 - 03:40 pm, CET
- mRNA-LNP Clinical Translation: Preclinical & CMC Considerations
- Thomas Madden
- President and CEO, Acuitas Therapeutics
- 03:40 - 03:55 pm, CET
- Strategies and considerations for mRNA manufacturing
- Laurens Vergauwen
- Process Development Scientist, Merck
- 03:55 - 04:10 pm, CET
- Oral abstract presentation - An engineered T7 RNA polymerase that generates immune-silent mRNA
- Athanasios Dousis
- Associate Scientific Director Molecular Engineering and Modeling, Moderna
Closing and passing of the baton
- 04:10 - 04:30 pm, CET
*subject to change and finalisation
